
Revolutionary Rosacea Treatment: Targeting Inflammatory Pathways

Harnessing p38 and Erk Kinase Inhibitors for Effective Management of Chronic Facial Inflammation

Background:

Rosacea is a chronic inflammatory skin condition affecting millions of people worldwide, characterized by facial redness, visible blood vessels, and sometimes acne-like bumps. The condition can be triggered by various factors, leading to persistent symptoms that significantly impact patients' quality of life. Traditional treatments have often focused on managing symptoms rather than addressing the underlying mechanisms of the disease. Recent research has identified the p38 and Erk kinase pathways as key players in the inflammatory response



Source: animalia-life.club

associated with rosacea. These signaling pathways are believed to be involved in the initial reaction to rosacea triggers, suggesting that their inhibition could potentially provide a more effective treatment approach.

Technology:

Scientists at Albany Medical center have developed a treatment for rosacea using inhibitors of the p38 and Erk kinase pathways. This technology aims to block or reduce the activity of these pathways, potentially interrupting the inflammatory cascade that leads to rosacea symptoms. Agents like Trametinib, which inhibits the Erk pathway, and other small molecule inhibitors targeting these pathways, are explored for their therapeutic potential. The patent also considers topical formulations for localized treatment, representing a shift from symptom management to addressing the underlying molecular mechanisms of rosacea, potentially offering more effective and targeted treatment options for patients suffering from this chronic skin condition.

Technology Readiness

Phase 1 complete - Ready for licensing

Advantages:

- Targeted approach
- Minimal systemic absorption
- Safety and tolerability
- Potential for broader applications

Applications:

- Treatment of rosacea
- Potential therapy for other forms of rosacea

Intellectual Property

US11065252B2

For inquiries please contact techtransfer@amc.edu Office for Translational Research Albany Medical College 43 New Scotland Ave, MC-25 Albany, NY 12208

